June 26, 2020 / 5:08 AM / 21 days ago

BRIEF-Vivoryon Therapeutics Provides Update On US And EU Alzheimer's Clinical Trial Program With PQ912

June 26 (Reuters) - Vivoryon Therapeutics AG:

* PROVIDES UPDATE ON US AND EU ALZHEIMER’S CLINICAL TRIAL PROGRAM WITH PQ912

* EU ALZHEIMER’S TRIAL VIVIAD IS EXPECTED TO START IN SECOND HALF OF 2020 DUE TO CORONAVIRUS PANDEMIC-RELATED DELAY Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below